Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for GVHD Prophylaxis in HSCT
NCT00141739Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Aug 2004
- Primary completion
- Aug 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of Participants Experiencing Acute GVHD at 100 days. Started Aug 2004; status: completed.
02
Drugs
etanercept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00141739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141739.